Chinese innovative drugs developer Allist Pharmaceuticals has raised RMB1.18 billion ($170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital, according to an announcement.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com